In Depth 27 Mar 2024 Are new treatments for multiple sclerosis on the horizon? As the wait for new multiple sclerosis treatments continue, here are some ongoing clinical trials that hold promise. March 27, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2024 Eight CAR-T cell therapy companies you should know about Discover eight promising biotech companies that are advancing their CAR T cell therapy candidates in the clinic. March 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Feb 2024 6 biotech companies making a difference in pediatric care Take a closer look at six pediatric companies taking innovative approaches to tackle illnesses affecting children. February 29, 2024 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 22 Feb 2024 TIL therapies: the impact on cancer research The approval of the first-ever TIL therapy has made it possible to treat hundreds of thousands of people affected by skin cancer in the US. February 22, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Turning the tide: recent advancements in childhood cancer research As we observe International Childhood Cancer Day today, let us take a look at some of the recent advancements in childhood cancer research. February 15, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Jan 2024 A new chapter in cell therapy: engineered B cells reach the clinic for the first time Cell therapy has drastically improved the scope of treatment for a number of diseases in the last few years. Now, engineered B cells are the latest approach in the field of cell therapy, having recently made it into clinical trials. But what exactly are B cells and how can they be engineered to treat diseases? […] January 24, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
More News! 4 Dec 2023 FDA CAR-T cell therapy warning: Are T cells malignant? Chimeric antigen receptor (CAR) T cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR-T cell therapy warning comes at […] December 4, 2023 - 4 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Podcast 13 Oct 2023Beyond Biotech podcast 67 – natural killer cells This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […] October 13, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 4 Oct 2023 CAR-NK: Can natural killer cell therapy pick up from where CAR-T left off? Riding on the success of CAR-T cell therapy, a breakthrough in the treatment of blood cancers, CAR-NK therapies are an emerging field in therapeutic research that aim to boost an even stronger immune response against cancer. What is CAR-NK cell therapy? Natural killer (NK) cells, like T cells, are white blood cells that are a […] October 4, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm Known throughout history for being home to the iconic scene of Hollywood, in recent years Los Angeles has also become a thriving biotech hub, after years of playing second fiddle in the U.S. to the likes of South San Francisco and Boston. In this article, we take a look at five of the best Los […] September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […] July 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2023 Kelonia presents ‘compelling evidence’ for transformative multiple myeloma treatment Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs). Kelonia’s iGPS platform enables CAR T cell therapy […] May 19, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email